Ureas

Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Retrieved on: 
Tuesday, June 8, 2021
Organic compounds, Chemical compounds, Atypical antipsychotics, Pimavanserin, Piperidines, Ureas, Portnoy, Food and Drug Administration, Psychosis, Chemistry

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.
  • The complaint alleges that Acadia misrepresented facts concerning their supplemental new drug application for NUPLAZID (pimavanserin), which treats dementia-related psychosis.
  • Thereafter, Acadia repeatedly stated the FDA had not identified any potential review issues, reiterating the efficacy of the drug.
  • The Portnoy Law Firm represents investors in pursuing arising from corporate wrongdoing.

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

Retrieved on: 
Wednesday, June 2, 2021
Medical specialties, Clinical medicine, Drugs, Rheumatology, Organofluorides, Pyrrolidines, Upadacitinib, Ureas, Rheumatoid arthritis, Adalimumab, Arthritis, Filgotinib

The integrated safety analysis included pooled data from six randomized, controlled RINVOQ rheumatoid arthritis clinical trials.

Key Points: 
  • The integrated safety analysis included pooled data from six randomized, controlled RINVOQ rheumatoid arthritis clinical trials.
  • Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 years From the SELECT-COMPARE Study.
  • Integrated Safety Profile of Upadacitinib With up to 4.5 Years of Exposure in Patients With Rheumatoid Arthritis (RA Integrated Safety Update).
  • Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 weeks from the SELECT-COMPARE Study.

Global Zilpaterol (CAS 119520-05-7) Market Research Report 2021 - Key Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Organic compounds, Chemistry, Chemical compounds, Benzazepines, Medicated feed, Ureas, Zilpaterol, Business process, Market research

b'The "Zilpaterol (CAS 119520-05-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Zilpaterol.

Key Points: 
  • b'The "Zilpaterol (CAS 119520-05-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Zilpaterol.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.\nThe Zilpaterol global market report key points:\n'

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma

Retrieved on: 
Wednesday, May 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Organic compounds, Chemical compounds, Aromatic compounds, Chloroarenes, Ureas, Pyridines, Sorafenib, FOTIVDA® (tivozanib), Advanced Renal Cell Carcinoma, AVEO Pharmaceuticals, Inc., FOTIVDA® (TIVOZANIB), ADVANCED RENAL CELL CARCINOMA, AVEO PHARMACEUTICALS, INC.

\xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.

Key Points: 
  • \xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.
  • Additional analyses and long-term follow up results from the TIVO-3 study to be presented at the 2021 ASCO Annual Meeting include:\nDurability of Response and Updated Overall Survival.
  • It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)

Retrieved on: 
Friday, April 30, 2021
Legal, Professional services, Organic compounds, Chemical compounds, Pimavanserin, Piperidines, Ureas, Linehan, Chemistry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210430005458/en/\n'

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Retrieved on: 
Friday, April 23, 2021
Legal, Professional services, Organic compounds, Chemical compounds, Pimavanserin, Piperidines, Ureas, Food and Drug Administration, Chemistry

If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.

Key Points: 
  • If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.
  • Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design and statistical problems.
  • The pimavanserin sNDA did not contain the support for its approval despite the Company telling investors that it did.
  • Based on these facts, the Company\xe2\x80\x99s public statements were false and materially misleading throughout the class period.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Retrieved on: 
Thursday, April 22, 2021
Legal, Professional services, Organic compounds, Chemical compounds, Pimavanserin, Piperidines, Ureas, Food and Drug Administration, Chemistry

If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.

Key Points: 
  • If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.
  • Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design and statistical problems.
  • The pimavanserin sNDA did not contain the support for its approval despite the Company telling investors that it did.
  • Based on these facts, the Company\xe2\x80\x99s public statements were false and materially misleading throughout the class period.

Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting

Retrieved on: 
Saturday, April 10, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Organic compounds, Chemical compounds, Chemistry, Chloroarenes, Pyridines, Regorafenib, Ureas, Tipiracil, Progression-free survival, Cancer, Etrumadenant, Arcus Biosciences

Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)

Key Points: 
  • Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)
    Median progression-free survival (PFS) of 4.2 months.
  • Reported data for current standard-of-care (SOC) therapies have shown a median PFS of 2.0 and 1.9 months for trifluridine-tipiracil and regorafenib, respectively3,4.
  • Reported data for trifluridine-tipiracil and regorafenib have shown a median OS of 7.1 and 6.4 months, respectively3,4.
  • Few options exist today to treat third-line colorectal cancer, and these therapies are associated with significant toxicity and limited efficacy.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Retrieved on: 
Tuesday, March 23, 2021
Orphan drugs, Chemical compounds, Organic compounds, Drugs, Chloroarenes, Ureas, Protein kinase inhibitors, Cyclopropanes, Lenvatinib, Merck & Co., Eisai, Thymic carcinoma

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.

Global Biotin Supplements Market (2020 to 2026) - Industry Analysis, Trends, Market Size, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 23, 2021
Food, Beverage, Retail, Organic compounds, Biotin, Cofactors, Ureas, Chemical compounds, Forecasting, Chemistry, Biotin deficiency

The "Biotin Supplements Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biotin Supplements Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global biotin supplements market provides qualitative and quantitative analysis for the period from 2018 to 2026.
  • The report predicts the global biotin supplements market to grow with a healthy CAGR over the forecast period from 2020-2026.
  • The report on biotin supplements market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biotin supplements market over the period of 2018 to 2026.